Saptalis Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SAPTALIS PHARMS
SAPTALIS PHARMS has ten approved drugs.
There are two US patents protecting SAPTALIS PHARMS drugs.
Summary for Saptalis Pharms
| US Patents: | 2 |
| Tradenames: | 10 |
| Ingredients: | 10 |
| NDAs: | 10 |
Drugs and US Patents for Saptalis Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Saptalis Pharms | LIKMEZ | metronidazole | SUSPENSION;ORAL | 216755-001 | Sep 22, 2023 | RX | Yes | Yes | 12,257,236 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Saptalis Pharms | CLOBETASOL PROPIONATE | clobetasol propionate | SOLUTION;TOPICAL | 211494-001 | Oct 2, 2019 | AT | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Saptalis Pharms | HYDROXYZINE HYDROCHLORIDE | hydroxyzine hydrochloride | SYRUP;ORAL | 220271-001 | Jun 11, 2026 | AA | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Saptalis Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Saptalis Pharms | MIACALCIN | calcitonin salmon | SPRAY, METERED;NASAL | 020313-002 | Aug 17, 1995 | 5,733,569 | ⤷ Start Trial |
| Saptalis Pharms | MIACALCIN | calcitonin salmon | SPRAY, METERED;NASAL | 020313-002 | Aug 17, 1995 | 5,759,565 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Saptalis Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 3087789 | ⤷ Start Trial |
| Canada | 3087789 | ⤷ Start Trial |
| European Patent Office | 3768321 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Saptalis Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2498758 | CR 2020 00017 | Denmark | ⤷ Start Trial | PRODUCT NAME: METFORMIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; SAXAGLIPTIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; DAPAGLIFLOZIN ELLER ET FARMACEUTISK ACCEPTABELT SOLVAT DERAF; REG. NO/DATE: EU/1/19/1401 20191113 |
| 1666481 | 300887 | Netherlands | ⤷ Start Trial | PRODUCT NAME: TOFACITINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER TOFACITINIBCITRAAT; REGISTRATION NO/DATE: EU/1/17/1178 20170324 |
| 1532149 | C300569 | Netherlands | ⤷ Start Trial | PRODUCT NAME: LINAGLIPTINE, DESGEWENST IN DE VORM VAN EEN ZOUT, IN COMBINATIE MET METFORMINEHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/12/780/001-028 20120720 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
